02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
22:57 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Cell culture and mouse studies suggest inhibiting EZH2 could help treat KDM6A-mutant MM. In three KDM6A-mutant human MM cell lines, two EZH2 inhibitor tool compounds decreased viability and increased apoptosis compared...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
00:11 , Mar 10, 2017 |  BC Innovations  |  Targets & Mechanisms

Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more...
00:51 , Jan 14, 2017 |  BioCentury  |  Politics, Policy & Law

Duck and cover

Biopharmaceutical industry CEOs and lobbyists tell BioCentury they have settled on a duck and cover strategy for coping with President-elect Donald Trump’s frontal attacks on the industry’s pricing policies and global supply chains. The idea...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Ublituximab: Phase II final data

Final data from 15 patients with previously treated mantle cell lymphoma (MCL) in the open-label, U.S. Phase II UTX-IB-104 trial showed that 900 mg IV ublituximab plus once-daily oral Imbruvica ibrutinib led to an ORR...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Clinical News

TGR-1202: Additional Phase I/II data

Additional data from 9 evaluable patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the open-label, dose-escalation, U.S. Phase I UTX-TGR-103 trial showed that ublituximab in combination with TGR-1202 led to...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Clinical News

Ublituximab: Additional Phase I/II data

Additional data from 9 evaluable patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the open-label, dose-escalation, U.S. Phase I UTX-TGR-103 trial showed that ublituximab in combination with TGR-1202 led to...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) Lysine-specific demethylase 6A (KDM6A; UTX); KDM6B (JMJD3) Cell culture and mouse studies suggest inhibiting JMJD3 could help treat T cell acute...
07:00 , Sep 11, 2014 |  BC Innovations  |  Targets & Mechanisms

A chromatin target for ALL

A New York University School of Medicine - GlaxoSmithKline plc collaboration has shown that an inhibitor of the chromatin regulator JMJD3 could help treat T cell acute lymphoblastic leukemia. 1 As JMJD3 is upregulated and...